Broxaterol

This classification denotes a beta-adrenergic agonist with the molecular formula C9H15BrN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ZE4IRB4DUC, chemically known as 3-bromo-alpha-(((1,1-dimethylethyl)amino)methyl)isoxazole-5-methanol but generally known as broxaterol, which bears US NIH Compound Identifier 71149. European Medicines Agency schedules Broxaterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05937MIG. The term BROXATEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 38, No. 6, 1984, List 24). BROXATEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule broxaterol under HS 29349990 and SITC 51579. As of Q4 2014, BROXATEROL remains the US FDA Preferred Term for this commodity. Broxaterol bears US NLM identifiers UMLS ID C0054156 and NCI Concept Code C74195. SMILES: BRC1NOC(C(O)CNC(C)(C)C)C1.